

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT4893425

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
KARYOPHARM THERAPEUTICS INC.	01/24/2018
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	BIOGEN MA INC.
<b>Street Address:</b>	225 BINNEY STREET
<b>City:</b>	CAMBRIDGE
<b>State/Country:</b>	MASSACHUSETTS
<b>Postal Code:</b>	02142
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	14747394
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(617)832-7000
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	6178321000
<b>Email:</b>	sjammal@foleyhoag.com
<b>Correspondent Name:</b>	SUSAN M. ABELLEIRA
<b>Address Line 1:</b>	155 SEAPORT BLVD.
<b>Address Line 2:</b>	FOLEY HOAG LLP
<b>Address Line 4:</b>	BOSTON, MASSACHUSETTS 02210
<b>ATTORNEY DOCKET NUMBER:</b>	KTQ-10003
<b>NAME OF SUBMITTER:</b>	SANDRA JAMMAL
<b>SIGNATURE:</b>	/Sandra Jammal/
<b>DATE SIGNED:</b>	03/30/2018
<b>Total Attachments: 8</b>	
source=KTQ-10003_Biogen_ASG#page1.tif	
source=KTQ-10003_Biogen_ASG#page2.tif	
source=KTQ-10003_Biogen_ASG#page3.tif	
source=KTQ-10003_Biogen_ASG#page4.tif	
source=KTQ-10003_Karyopharm_ASG#page1.tif	

source=KTQ-10003\_Karyopharm\_ASG#page2.tif

source=KTQ-10003\_Karyopharm\_ASG#page3.tif

source=KTQ-10003\_Karyopharm\_ASG#page4.tif

PATENT ASSIGNMENT

This PATENT ASSIGNMENT (the “Assignment”) is made and entered into as of this 24<sup>th</sup> day of January, 2018 (the “Closing Date”), by and between **Karyopharm Therapeutics Inc.**, having its principal place of business at 85 Wells Avenue, Newton, MA 02459 United States of America (hereinafter “Assignor”), and **Biogen MA Inc.**, having its principal place of business at 225 Binney Street, Cambridge, Massachusetts 02142, United States of America (hereafter “Assignee”).

For good and valuable consideration, the receipt, adequacy and legal sufficiency of which is hereby acknowledged, Assignor does hereby sell, assign and transfer unto said Assignee, its successors and assigns, the entire interest for the United States of America, and its possessions and territories, and all foreign countries jurisdictions, in, to, and for (1) certain inventions or improvements described in the patent application and patents identified in **Schedule A** to this Patent Assignment, which Schedule A is attached hereto and incorporated herein by reference (collectively, the “Patents and Patent Applications”), (2) the Patents and Patent Applications, (3) all patents of the United States and its possessions and territories and of all foreign countries and jurisdictions which may or shall be granted on said invention(s), on said improvement(s), or on said Patent Application(s), (4) all provisional, divisional, continuation, reissue, PCT, national phase, or other applications based on said Patents and Patent Applications, and (5) all rights of priority, including the right to claim priority under the Paris Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and any other treaty relating thereto, in each case that may arise from the Patents and Patent Applications, together with all rights to sue for past, present, or future infringement thereof, including the right to collect damages for any past infringement thereto.

Assignor agrees with said Assignee, but at Assignee’s expense, hereafter to execute all applications, amended specifications, deeds or other instruments, and to do all acts necessary or proper to secure the grant of patents in the United States and its possessions and territories and in all other foreign countries and jurisdictions to said Assignee, and to vest and confirm in said Assignee, its successors and assigns, the legal title to all such patents.

Assignor hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States and equivalent authorities in all patent offices worldwide to issue all patents that shall be granted on the Patent Applications or to transfer all Patents to said Assignee, its successors and assigns. This Assignment may be executed in any number of counterparts, including by facsimile copies or by electronic copies delivered by email, each of which will be deemed an original, with the same effect as if the signatures were upon the same instrument.

*[Signature page follows]*

Karyopharm Therapeutics Inc.

By \_\_\_\_\_

Title \_\_\_\_\_

Date \_\_\_\_\_

Witness Signature \_\_\_\_\_

Print Witness Name \_\_\_\_\_


Address \_\_\_\_\_

Witness Signature \_\_\_\_\_

Print Witness Name \_\_\_\_\_


Address \_\_\_\_\_

Biogen MA Inc.

By 


Title EVP, Research & Development

Date Jan 24, 2018

Witness Signature 

Print Witness Name Ryan J. Beltrami

Address 225 Binney Street  
Cambridge, MA 02142

Witness Signature 

Print Witness Name Elizabeth Conil

Address 225 Binney Street, Cambridge MA 02142

[Signature Page to Patent Assignment]

Schedule A  
Seller IP

Country	Application Status	Application No.	Filing Date	Publication No./ Publication Date	Patent No./ Patent Date
US Prov.	Expired	61/644,802	09-May-12		
US Prov.	Expired	61/798,188	15-Mar-13		
US	Granted	13/891,044	09-May-13	2013/0317031 28-Nov-2013	9,096,543 04-Aug-2015
PCT	Expired – PCT DOR Met	PCT/US2013/0404 04	09-May-13	WO2013/0170068 14-Nov-2013	
US	Granted	14/399,868	09-May-13	20150111893 23-Apr-2015	9,266,843 23-Feb-2016
AU	Granted	2013259384	09-May-13		2013259384 15-Sep-2016
BR	Pending	BR1120140278601	09-May-13		
CA	Pending	2872190	09-May-13	2872190 14-Nov-2013	
CL	Pending	030542014	09-May-13	0003054 15-May-2015	
CN	Granted	201380036570X	09-May-13	CN104428295A 18-Mar-2015	ZL20138003657 0x 08-Aug-2017
CO	Granted	14256418	09-May-13	242 19-Feb-2015	14256418 12-Dec-2016
EG	Pending	1769/2014	09-May-13		
EA	Pending	201492050	09-May-13	201492050 30-Jul-2015	
EP	Pending (Allowed)	13779943.3	09-May-13	2858991 15-Apr-2015	
GE	Pending	1365301	09-May-13		
IN	Pending	9434DELNP2014	09-May-13		
ID	Pending	P00201407662	09-May-13	02227 01-Apr-2016	
JP	Granted	2015511713	09-May-13		6195909 25-Aug-2017

Country	Application Status	Application No.	Filing Date	Publication No./ Publication Date	Patent No./ Patent Date
KR	Pending	1020147034556	09-May-13	1020150018809 24-Feb-2015	
MX	Pending	MXa2014013551	09-May-13		
NZ	Granted	702663	09-May-13		702663 04-Jul-2017
PE	Pending	0019972014DIN	09-May-13	075OP12030968 23-Feb-2015	
SG	Granted	11201407268S	09-May-13		11201407268S 20-Oct-17
ZA	Pending	201408140	09-May-13		
TH	Pending	1401006681	09-May-13		
UA	Pending (Allowed)	201413015	09-May-13		
UZ	Pending	IAP20140517	09-May-13		
VN	Pending	1201404067	09-May-13		
US	Pending (Allowed)	14/747394	23-Jun-15	20160145246 26-May-2016	
US	Granted	14/989377	06-Jan-16		9,585,874 07-Mar-2017
Hong Kong	Pending	15110056.3	09-May-13	1209420 01-Apr-2016	
AU	Pending	2016222459	09-May-13		
US	Pending	15/413889	24-Jan-17	20170319551 09-Nov-2017	
US	Pending	15/831048	04-Dec-17		
U.S. Prov.	Pending	62/426957	28-Nov-16		
PCT	Pending	PCT/US17/63439	28-Nov-17		

PATENT ASSIGNMENT

This PATENT ASSIGNMENT (the “Assignment”) is made and entered into as of this 24<sup>th</sup> day of January, 2018 (the “Closing Date”), by and between **Karyopharm Therapeutics Inc.**, having its principal place of business at 85 Wells Avenue, Newton, MA 02459 United States of America (hereinafter “Assignor”), and **Biogen MA Inc.**, having its principal place of business at 225 Binney Street, Cambridge, Massachusetts 02142, United States of America (hereafter “Assignee”).

For good and valuable consideration, the receipt, adequacy and legal sufficiency of which is hereby acknowledged, Assignor does hereby sell, assign and transfer unto said Assignee, its successors and assigns, the entire interest for the United States of America, and its possessions and territories, and all foreign countries jurisdictions, in, to, and for (1) certain inventions or improvements described in the patent application and patents identified in **Schedule A** to this Patent Assignment, which Schedule A is attached hereto and incorporated herein by reference (collectively, the “Patents and Patent Applications”), (2) the Patents and Patent Applications, (3) all patents of the United States and its possessions and territories and of all foreign countries and jurisdictions which may or shall be granted on said invention(s), on said improvement(s), or on said Patent Application(s), (4) all provisional, divisional, continuation, reissue, PCT, national phase, or other applications based on said Patents and Patent Applications, and (5) all rights of priority, including the right to claim priority under the Paris Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and any other treaty relating thereto, in each case that may arise from the Patents and Patent Applications, together with all rights to sue for past, present, or future infringement thereof, including the right to collect damages for any past infringement thereto.


Assignor agrees with said Assignee, but at Assignee’s expense, hereafter to execute all applications, amended specifications, deeds or other instruments, and to do all acts necessary or proper to secure the grant of patents in the United States and its possessions and territories and in all other foreign countries and jurisdictions to said Assignee, and to vest and confirm in said Assignee, its successors and assigns, the legal title to all such patents.

Assignor hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States and equivalent authorities in all patent offices worldwide to issue all patents that shall be granted on the Patent Applications or to transfer all Patents to said Assignee, its successors and assigns. This Assignment may be executed in any number of counterparts, including by facsimile copies or by electronic copies delivered by email, each of which will be deemed an original, with the same effect as if the signatures were upon the same instrument.

*[Signature page follows]*

Karyopharm Therapeutics Inc.


By



Title EVP, Chief Business Officer, General Counsel, and Secretary

Date 1/24/18

Witness Signatures



Print Witness Name


Lee G. Giguere

Address

85 Wells Avenue, Suite 210

Newton MA 02459

Witness Signature



Print Witness Name

Chris Robillard

Address

85 Wells Avenue, Suite 210 Newton, MA 02459

Biogen MA Inc.

By

Title

Date



Schedule A  
Seller IP

Country	Application Status	Application No.	Filing Date	Publication No./ Publication Date	Patent No./ Patent Date
US Prov.	Expired	61/644,802	09-May-12		
US Prov.	Expired	61/798,188	15-Mar-13		
US	Granted	13/891,044	09-May-13	2013/0317031 28-Nov-2013	9,096,543 04-Aug-2015
PCT	Expired – PCT DOR Met	PCT/US2013/0404 04	09-May-13	WO2013/0170068 14-Nov-2013	
US	Granted	14/399,868	09-May-13	20150111893 23-Apr-2015	9,266,843 23-Feb-2016
AU	Granted	2013259384	09-May-13		2013259384 15-Sep-2016
BR	Pending	BR1120140278601	09-May-13		
CA	Pending	2872190	09-May-13	2872190 14-Nov-2013	
CL	Pending	030542014	09-May-13	0003054 15-May-2015	
CN	Granted	201380036570X	09-May-13	CN104428295A 18-Mar-2015	ZL20138003657 0x 08-Aug-2017
CO	Granted	14256418	09-May-13	242 19-Feb-2015	14256418 12-Dec-2016
EG	Pending	1769/2014	09-May-13		
EA	Pending	201492050	09-May-13	201492050 30-Jul-2015	
EP	Pending (Allowed)	13779943.3	09-May-13	2858991 15-Apr-2015	
GE	Pending	1365301	09-May-13		
IN	Pending	9434DELNP2014	09-May-13		
ID	Pending	P00201407662	09-May-13	02227 01-Apr-2016	
JP	Granted	2015511713	09-May-13		6195909 25-Aug-2017

Country	Application Status	Application No.	Filing Date	Publication No./ Publication Date	Patent No./ Patent Date
KR	Pending	1020147034556	09-May-13	1020150018809 24-Feb-2015	
MX	Pending	MXa2014013551	09-May-13		
NZ	Granted	702663	09-May-13		702663 04-Jul-2017
PE	Pending	0019972014DIN	09-May-13	075OP12030968 23-Feb-2015	
SG	Granted	11201407268S	09-May-13		11201407268S 20-Oct-17
ZA	Pending	201408140	09-May-13		
TH	Pending	1401006681	09-May-13		
UA	Pending (Allowed)	201413015	09-May-13		
UZ	Pending	IAP20140517	09-May-13		
VN	Pending	1201404067	09-May-13		
US	Pending (Allowed)	14/747394	23-Jun-15	20160145246 26-May-2016	
US	Granted	14/989377	06-Jan-16		9,585,874 07-Mar-2017
Hong Kong	Pending	15110056.3	09-May-13	1209420 01-Apr-2016	
AU	Pending	2016222459	09-May-13		
US	Pending	15/413889	24-Jan-17	20170319551 09-Nov-2017	
US	Pending	15/831048	04-Dec-17		
U.S. Prov.	Pending	62/426957	28-Nov-16		
PCT	Pending	PCT/US17/63439	28-Nov-17		